Define Your DSAs with Greater Confidence LABScreen™ Single Antigen ExPlex

The powerful next step for HLA donor specific antibody (DSA) testing is available with the new LABScreen Single Antigen ExPlex!

Building on the trusted LABScreen Single Antigen platform, ExPlex now offers an extended HLA antibody panel in a single-well setup! Paired with the original LABScreen SABs, ExPlex provides cutting-edge capabilities with a total of 151 Class I and 119 Class II Common and Well-Documented alleles.
These increased specificities may provide broader antibody data to evaluate eplet patterns and complement your molecular donor typing results.

  • Total of 151 Class I or 119 Class II CWD alleles in a single well
  • Enhanced antibody coverage to better correlate with molecular typing results
  • Provides broader antibody reactivity data to evaluate eplet patterns
  • Easily integrates into your workflow with the LABScan3D

For In Vitro Diagnostic Use.

| How It Works

Simple Workflow – Single Well Setup

AllType workflow step 1 "sample preparation" graphic

Combine

  • ExPlex SAB (5 ul)
  • SAB (5 ul)
  • Serum (40 ul
AllType workflow step 2 "sequencing" graphic

Read

Read on LS3D

AllType workflow step 3 "analysis" graphic

Test

Test in a single well

 

| Assay Coverage

LABScreen Single Antigen HLA Class I & II ExPlex

HLA Class I – 54 additional single antigens

HLA Class II – 24 additional single antigens

Have questions about LABScreen Single Antigen ExPlex?
Request more information
Is LABScreen Single Antigen ExPlex right for your lab?
Request a demo of assays, equipment, and software

Featured Resources

References
  1. Zhang X, Reinsmoen NL. Impact of Non-Human Leukocyte Antigen-Specific Antibodies in Kidney and Heart Transplantation. Front Immunol. 2017 Apr 13;8:434
  2. Lopez-Soler RI, Borgia JA, Kanangat S, Fhied CL, Conti DJ, Constantino D, Ata A, Chan R, Wang Z. Anti-vimentin Antibodies Present at the Time of Transplantation May Predict Early Development of Interstitial Fibrosis/Tubular Atrophy. Transplant Proc. 2016 Jul-Aug;48(6):2023-33
  3. Carter V, Howell, WM. Vimentin antibody production in transplant patients and immunomodulatory effects of vimentin in-vitro. Human Immunology. 2013 Nov;74(11):1463-9
  4. Li L, Sigdel T, Vitalone M, Lee SH, Sarwal M, Differential immunogenicity and clinical relevance of kidney compartment specific antigens after renal transplantation. J Proteome Res. 2010 Dec 3;9(12):6715-21
  5. Li L, Wadia P, Chen R, Kambham N, Naesens M, Sigdel TK, et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and ‘‘antibodyome’’ measures. Proc Natl Acad Sci USA 2009;106(11):4148
  6. Dinavahi R, George A, Tretin A, Akalin E, Ames S, Bromberg JS, Deboccardo G, Dipaola N, Lerner SM, Mehrotra A, Murphy BT, Nadasdy T, Paz-Artal E, Salomon DR, Schröppel B, Sehgal V, Sachidanandam R, Heeger PS. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol. 2011 Jun;22(6):1168-78
  7. Sigdel TK, Li L, Tran TQ, Khatri P, Naesens M, Sansanwal P, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012;23(4):750
  8. Joosten SA, Sijpkens YW, van Ham V, Trouw LA, van der Vlag J, van den Heuvel B, van Kooten C, Paul LC. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant. 2005 Feb;5(2):383-93
  9. Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep. 2015 Mar 5;5:8803
  10. Burke GW 3rd, Vendrame F, Virdi SK, Ciancio G, Chen L, Ruiz P, Messinger S, Reijonen HK, Pugliese A. Lessons From Pancreas Transplantation in Type 1 Diabetes: Recurrence of Islet Autoimmunity. Curr Diab Rep. 2015 Dec;15(12):121
  11. Wiberg A, Granstam A, Ingvast S, Härkönen T, Knip M, Korsgren O, Skog O. Characterization of human organ donors testing positive for type 1 diabetes-associated autoantibodies. Clin Exp Immunol. 2015 Dec;182(3):278-88
  12. Pugliese A, Reijonen HK, Nepom J, Burke GW 3rd. Recurrence of autoimmunity in pancreas transplant patients: research update. Diabetes Manag (Lond). 2011 Mar; 1(2): 229–238
  13. van der Pijl JW, Boonstra JG, Barthellemy S, Smets YF, Hermans J, Bruijn JA, de Fijter JW, Daha MR, Dagorn JC. Pancreatitis-associated protein: a putative marker for pancreas graft rejection. Transplantation. 1997 Apr 15;63(7):995-1003
  14. Shi J, Li Y, Yang X, Yang D, Zhang Y, Liu Y. Upregulation of α-enolase in acute rejection of cardiac transplant in rat model: implications for the secretion of interleukin-17. Pediatr Transplant. 2014 Sep;18(6):575-85
  15. Ationu A. Identification of endothelial antigens relevant to transplant coronary artery disease from a human endothelial cell cDNA expression library. Int J Mol Med. 1998 Jun; 1:1007–1010
  16. Kalache S, Dinavahi R, Pinney S, Mehrotra A, Cunningham MW, Heeger PS. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immuno. 2011 Jul 15;187(2):1023-30
  17. Nath DS, Ilias Basha H, Tiriveedhi V, Alur C, Phelan D, Ewald GA, Moazami N, Mohanakumar T. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant. 2010;29(11):1277-85
  18. Acevedo MJ, Caro-Oleas JL, Alvarez-Marquez AJ, Sobrino JM, Lage-Galle E, Aguilera I, et al. Antibodies against heterogeneous nuclear ribonucleoprotein K in patients with cardiac allograft vasculopathy. J Heart Lung Transplant 2011;30(9):1051
  19. Tiriveedhi V, Gautam B, Sarma NJ, Askar M, Budev M, Aloush A, Hachem R, Trulock E, Myers B, Patterson AG, Mohanakumar T. Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations. The Journal of Heart and Lung Transplantation. 2013 Aug;32(8):807-14
  20. Hachem RR, Tiriveedhi V, Patterson GA, Aloush A, Trulock EP, Mohanakumar T. Antibodies to K-α 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant. 2012 Aug;12(8):2164-71
  21. Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008;180(7):4487.
  22. Wadia PP, Coram M, Armstrong RJ, Mindrinos M, Butte AJ, Miklos DB. Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Blood 2010;115(10):2077
  23. Aguilera I, Sousa JM, Núñez-Roldán A. Clinical relevance of GSTT1 mismatch in solid organ and hematopoietic stem cell transplantation. Hum Immunol. 2013 Nov;74(11):1470-3
  24. Alvarez-Márquez A, Aguilera I, Gentil MA, Caro JL, Bernal G, Fernández Alonso J, Acevedo MJ, Cabello V, Wichmann I, Gonzalez-Escribano MF, Núñez-Roldán A. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation. 2009 Jan 15;87(1):94-9
  25. Aguilera I, Sousa JM, Gavilán F, Bernardos A, Wichmann I, Nuñez-Roldán A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl. 2004 Sep;10(9):1166-72
  26. Cardinal H, Dieudé M, Hébert MJ. The Emerging Importance of Non-HLA Autoantibodies in Kidney Transplant Complications. J Am Soc Nephrol. 2016 Oct 17
  27. Cardinal H, et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant. 2013 Apr;13(4):861-74
  28. Joosten SA, van Dixhoorn MG, Borrias MC, et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 1301–1310.
  29. Bakker RC, Koop K, Sijpkens YW, Eikmans M, Bajema IM, De Heer E, Bruijn JA, Paul LC. Early interstitial accumulation of collagen type I discriminates chronic rejection from chronic cyclosporine nephrotoxicity. J Am Soc Nephrol. 2003 Aug;14(8):2142-9
  30. Angaswamy N, Klein C, Tiriveedhi V, Gaut J, Anwar S, Rossi A, Phelan D, Wellen JR, Shenoy S, Chapman WC, Mohanakumar T. Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy. Am J Transplant. 2014 Mar;14(3):685-93
  31. Tiriveedhi V, Angaswamy N, Brand D, Weber J, Gelman AG, Hachem R, et al. A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol 2012;167(1):158.
  32. Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007;117(11):3498.
  33. Haque MA, Mizobuchi T, Yasufuku K, Fujisawa T, Brutkiewicz RR, Zheng Y, Woods K, Smith GN, Cummings OW, Heidler KM, Blum JS, Wilkes DS. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol. 2002 Aug 1;169(3):1542-9